27 July 2018 - Australians with head and neck cancer will from next week have affordable access to an immuno-oncology drug, which up until now has cost about $100,000 for the treatment.

The drug, Bristol-Myers Squibb’s Opdivo, gave Brisbane man David Littlewood hope for a longer life when his cancer returned last year. He said if he had not been put on a drug trial for Opdivo, he would not have been able to afford the life-saving treatment.

“Immunotherapy was my last chance to tackle terminal cancer,” he said.

Read The Australian article